Nanobiotix Appoints Bart Van Rhijn as New Chief Financial Officer
Biotechnology company Nanobiotix has appointed Bart Van Rhijn as its new Chief Financial Officer and a member of the Executive Board. The move supports the company's global expansion plans.
Paris, France; Cambridge, Massachusetts – Nanobiotix, a biotechnology company, has appointed Bart Van Rhijn as its new Chief Financial Officer and a member of the Executive Board. This appointment is intended to support the company's global expansion initiatives.
Van Rhijn joins Nanobiotix from Servier Pharmaceuticals, where he served as CFO for nearly three years. He brings extensive experience in global financial management, business development, and pharmaceutical commercialization. The company is preparing for the planned launch of its second clinical registration study for its radioenhancer NBTXR3 in head and neck cancer, along with further development in immunotherapy and expansion into other solid tumor types.
He succeeds Philippe Mauberna, who is stepping down from his roles after eight years of service. Mauberna will assume a temporary role to support the transition. Nanobiotix has previously received European market approval for NBTXR3 (Hensify®) for the treatment of soft tissue sarcoma.
CEO Laurent Levy stated that Van Rhijn's competencies in scaling commercialization are critical as Nanobiotix advances toward potential global commercialization and aims to bring its novel technologies to patients worldwide.